AICDA and cancer: The major challenges for the CRISPRa-based therapies include (a) the lack of effective CRISPR/Cas delivery methods; (2) the transient nature of CRISPRa activation; and (3) potential pro-mutagenic activity of APOBEC/AID factors that may contribute to mutation showers and development of cancer.